Proposal of Optomed’s Nomination Board
Optomed Plc Stock Exchange Release 3 February 2020 at 9:30, Helsinki
Proposal of Optomed’s Nomination Board
Optomed’s Nomination Board proposes the following to the next Annual General Meeting 2020:
Number of Board members
The Nomination Board proposes, that the number of members of the Board of Directors for the term expiring at the close of the Annual General Meeting 2021 is five.
Composition of the Board of Directors
The Nomination Board proposes to the Annual General Meeting that:
- Seppo Mäkinen, Petri Salonen, Reijo Tauriainen and Jun Wu are re-elected as Board members
- Anna Tenstam is elected as a new Board member
Anna Tenstam (MSc, MBA, born 1964, a Swedish citizen) is the CEO and co-founder of Datum Aesthetics. Previously, she has served as the CEO and Chairman of Eternogen in the US and has strong international experience from the medical sector including various board positions and exits. She is independent of Optomed and its major shareholders.
Proposal for the remuneration of the Board of Directors
The Nomination Board proposes to the Annual General Meeting that the annual remuneration payable to the members of the Board of Directors to be elected at the Annual General Meeting for the term until the close of the Annual General Meeting in 2021 be as follows:
- EUR 36,000 for the Chairman of the Board
- EUR 18,000 for each Board member
In addition, the Nomination Board proposes that a meeting fee in the amount of EUR 500 is paid to the Audit Committee chairman for each Audit Committee meeting. The Shareholders’ Nomination Board proposes that 40 % of the Board remuneration is paid in Optomed shares and 60 % in cash. The remuneration will be paid once a year in August, after Optomed’s H1 report has been announced.
Nomination Board
Optomed’s nomination board consists of the following individuals:
- Hai Wu (appointed by Jun Wu’s controlled entities)
- Jarmo Malin (appointed by Aura Capital Oy)
- Ville Talasmäki (appointed by Mandatum Life Insurance Company)
Petri Salonen (chairman of Optomed’s Board of Directors) serves as the Nomination Board's expert member and Jarmo Malin acts as the chairman of the Nomination Board.
Optomed Plc
Further enquiries
Jarmo Malin, Chairman of the Nomination Board, jarmo.malin@auratum.com
Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com
Distribution
Nasdaq Helsinki Ltd
Principal media
Optomed in Brief
Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 52 international patents protecting the technology. In 2018, Optomed’s revenue reached EUR 12.7 million and pro forma revenue with the acquisition of Commit; Oy amounted to EUR 14.5 million. At the end of September 2019, Optomed employed 105 professionals.